Table 4. Description of the data sets used in this study.
| HEBCS GWS | POSH GWS | SUCCESS-A | iCOGS | |
|---|---|---|---|---|
| No. of cases | 805 | 536 | 3596 | 17828 |
| Vital status | ||||
| Alive | 466 (58%) | 300 (56%) | 3389 (94%) | 15630 (88%) |
| Deceased: all-cause | 339 (42%) | 236 (44%) | 207 (6%) | 2198 (12%) |
| Follow-up mean ±SD (years) | 10.6 ± 6.6 | 4.1 ± 2.0 | 3.9 ± 1.7 | 7.3 ± 4.0 |
| Age at diagnosis, mean [range) | 54.1 [22 - 87] | 35.8 [18 - 41] | 53.6 [19 - 85] | 55.2 [19 — 95] |
| ER | ||||
| Negative | 230 (29%) | 370 (69%) | 1106 (31%) | 3002 (17%) |
| Positive | 513 (64%) | 165 (31%) | 2458 (68%) | 11753(66%) |
| Missing data | 62 (8%) | 1 (0.2%) | 32 (1%) | 3073 (17%) |
| Grade | ||||
| 1 | 144 (18%) | 13 (2%) | 165 (5%) | 2911 (16%) |
| 2 | 312 (39%) | 84 (16%) | 1698 (47%) | 6354 (36%) |
| 3 | 280 (35%) | 422 (79%) | 1698(47%) | 4414 (25%) |
| Missing data | 69 (9%) | 17 (3%) | 35 (1%) | 4149 (23%) |
| T / tumor size category a | ||||
| 1 | 390 (48%) | 232 (43%) | 1464(41%) | 9338 (52%) |
| 2 | 304 (38%) | 236 (44%) | 1856 (52%) | 4615 (26%) |
| 3 | 50 (6%) | 49 (9%) | 192 (5%) | 635 (4%) |
| 4 | 47 (6%) | 12 (2%) | 50 (1%) | n/a |
| Missing data | 14 (2%) | 7(1%) | 34 (1%) | 3240 (18%) |
| N (nodal metastasis) | ||||
| Negative | 338 (42%) | 248 (46%) | 1248 (35%) | 8976 (50%) |
| Positive | 446 (55%) | 262 (49%) | 2311 (64%) | 5471 (31%) |
| Missing data | 21 (3%) | 26 (5%) | 37 (1%) | 3381 (19%) |
| M (distant metastasis) | ||||
| Negative | 740 (92%) | 481 (90%) | 3487 (97%) | 2834 (16%) |
| Positive | 57 (7%) | 50 (9%) | 4 (0.1%) | 267 (1.5%) |
| Missing data | 8 (1%) | 5(1%) | 105 (2.9%) | 14727(83%) |
| Adjuvant chemotherapy treatment | ||||
| No adjuvant chemotherapy | 445 (55%) | 18 (3.4%) | 0 (0%) | 11108 (62%) |
| Anthracycline+Taxane | 14 (2%) | 129 (24%) | 3596 (100%) | 733 (4%) |
| Anthracycline | 191 (24%) | 375 (70%) | - | 2277 (13%) |
| Taxane | 2 (0.2%) | 8 (1.5%) | - | 135 (0.8%) |
| Methotrexate | 153 (19%) | 4 (0.7%) | - | 1022 (6%) |
| Missing data | - | - | - | 2528 (14%) |
| Adjuvant Endocrine treatment | ||||
| Treated | 282 (35%) | 183 (34%) | 2458 (68%) | 11340 (64%) |
| Not treated | 520 (65%) | 344 (64%) | 1138 (32%) | 5670 (32%) |
| Missing data | 3 (0.4%) | 9 (1.7%) | - | 818 (5%) |
a
T was acquired from TNM staging for HEBCS, POSH, SUCCESS-A, and derived from tumor diameter in COGS (1: s2crn. 2: >2cm and s5cm, 3: >5cm); T4 (inflammatory carcinoma) is therefore undefined for COGS.